| VG Life Sciences, Inc. operates as a development stage biotechnology company, which engages on discovering and developing drug therapies for cancer, infectious disease, and inflammatory autoimmune disorders. The company is currently focused on researching two technologies namely Targeted Peptide Technology which targets the body's immune cells and seems to explain the mechanism behind some autoimmune diseases while presenting a possible solution and Metabolic Disruption Technology which can be used in combination with a variety of existing drugs and compounds to treat drug resistant cancers. The company was founded by Haig Keledjian in 1994 and is headquartered in San Marino, CA. |
